Who can use Alhemo(Concizumab)?

Alhemo (concizumab-mtci) is indicated for adult and pediatric patients aged 12 years and older with hemophilia A or B who have developed factor VIII or IX inhibitors.

Who can use Alhemo(Concizumab)?

It is used for routine prophylaxis to prevent or reduce bleeding episodes. Eligible patients must be able to receive subcutaneous injections, with dosing tailored to body weight (loading dose: 1 mg/kg, followed by maintenance doses adjusted based on plasma concentrations).

Contraindications include known hypersensitivity to the drug or its components. Caution is advised in patients with thromboembolic risk factors, as Alhemo may increase thrombotic risk, especially when used with bypassing agents like rFVIIa or aPCC. Safety in pregnant/lactating individuals and those under 12 years is unestablished. Patients should be monitored for thromboembolic events and hypersensitivity reactions during treatment.